Production (Stage)
X4 Pharmaceuticals, Inc.
XFOR
$3.10
-$0.13-4.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.85% | 52.56% | 92.55% | 30.13% | 140.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.58% | 47.42% | 28.83% | 33.54% | 27.25% |
| Operating Income | 74.68% | -41.73% | -26.77% | -31.36% | -27.25% |
| Income Before Tax | 100.61% | -107.17% | -1,509.52% | 263.12% | -115.47% |
| Income Tax Expenses | 78.95% | 681.82% | -42.31% | 20.00% | 375.00% |
| Earnings from Continuing Operations | 100.54% | -108.16% | -1,492.02% | 263.04% | -115.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 100.54% | -108.16% | -1,492.02% | 263.04% | -115.51% |
| EBIT | 74.68% | -41.73% | -26.77% | -31.36% | -27.25% |
| EBITDA | 75.91% | -41.00% | -26.27% | -31.25% | -27.59% |
| EPS Basic | 100.53% | -103.89% | -1,461.45% | 237.25% | -57.30% |
| Normalized Basic EPS | 100.60% | -102.91% | -1,478.61% | 78.61% | -57.27% |
| EPS Diluted | 100.51% | -103.07% | -1,461.45% | 236.29% | -57.39% |
| Normalized Diluted EPS | 100.59% | -102.91% | -1,478.61% | 78.65% | -57.27% |
| Average Basic Shares Outstanding | 2.60% | 2.10% | 1.97% | 18.79% | 37.01% |
| Average Diluted Shares Outstanding | 3.04% | 2.10% | 1.97% | 19.00% | 37.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |